Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales
Pharmacy · 21.09.2024 · 12 (5) · 142
DOI: 10.3390/pharmacy12050142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacy, online erschienen am 21.09.2024. Verfasst von Gianpiero Tebano und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, Ravenna Hospital, AUSL Romagna, 48100 Ravenna, Italy. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
AmpC enzymes are a class of beta-lactamases produced by Gram-negative bacteria, including several Enterobacterales. When produced in sufficient amounts, AmpCs can hydrolyze third-generation cephalosporins (3GCs) and piperacillin/tazobactam, causing resistance. In Enterobacterales, the AmpC gene can be chromosomal- or plasmid-encoded. Some species, particularly Enterobacter cloacae complex, Klebsiella aerogenes, and Citrobacter freundii, harbor an inducible chromosomal AmpC gene. The expression of this gene can be derepressed during treatment with a beta-lactam, leading to AmpC overproduction and the consequent emergence of resistance to 3GCs and piperacillin/tazobactam during treatment. Because of this phenomenon, the use of carbapenems or cefepime is considered a safer option when treating these pathogens. However, many areas of uncertainty persist, including the risk of derepression related to each beta-lactam; the role of piperacillin/tazobactam compared to cefepime; the best option for severe or difficult-to-treat cases, such as high-inoculum infections (e.g., ventilator-associated pneumonia and undrainable abscesses); the role of de-escalation once clinical stability is obtained; and the best treatment for species with a lower risk of derepression during treatment (e.g., Serratia marcescens and Morganella morganii). The aim of this review is to collate the most relevant information about the microbiological properties of and therapeutic approach to AmpC-producing Enterobacterales in order to inform daily clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Diseases Unit, Ravenna Hospital, AUSL Romagna, 48100 Ravenna, Italy.
- Department of Infectious Diseases, University Hospital of Galway, H91 Galway, Ireland.
- Unit of Microbiology, The Greater Romagna Area Hub Laboratory, 47522 Cesena, Italy.
- Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, 40126 Bologna, Italy.
- Infectious Diseases Unit, Forlì and Cesena Hospitals, AUSL Romagna, 47121 Forlì and Cesena, Italy.
ORCID-Profile: Monica Cricca, Francesco Cristini
Zitieren
APA
Tebano, G., Zaghi, I., Cricca, M., & Cristini, F. (2024). Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales. Pharmacy, 12(5), 142. https://doi.org/10.3390/pharmacy12050142
Vancouver
Tebano G, Zaghi I, Cricca M, Cristini F. Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales. Pharmacy. 2024;12(5):142. doi:10.3390/pharmacy12050142
BibTeX
@article{Tebano2024,
author = {Tebano, Gianpiero and Zaghi, Irene and Cricca, Monica and Cristini, Francesco},
title = {Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales},
journal = {Pharmacy},
year = {2024},
volume = {12},
number = {5},
pages = {142},
doi = {10.3390/pharmacy12050142}
}
EUVIMED